Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged appeared first on Investor's Business Daily.
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten
Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. If all goes well, it could be approved by September 2025. Aficamten had favorable Phase 3 data, so it could have solid competitive prospects if approved, possibly with better safety and simpler dosing. Although CYTK looks a bit pricey today, Aficamten's $10 billion TAM by 2035 makes CYTK's valuation much more reasonable.
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA approval.
Cytokinetics, Incorporated (CYTK) Q4 2024 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate Affairs Robert Blum - President & Chief Executive Officer Andrew Callos - Executive Vice President & Chief Commercial Officer Fady Malik - Executive Vice President, R&D Isaac Ciechanover - EVP Corporate Development and Chief Business Officer Stuart Kupfer - Senior Vice President & Chief Medical Officer Sung Lee - Executive Vice President & Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Cory Kasimov - Evercore ISI Salim Syed - Mizuho James Condulis - Stifel Tess Romero – JPMorgan Leonid Timashev - RBC Capital Markets Akash Tewari - Jefferies David Lebowitz - Citi Sean McCutcheon - Raymond James Srikripa Devarakonda - Truist Securities Roanoke Ruiz - Leerink Partners Joe Pantginis - H. C. Wainwright Mayank Mamtani - B.
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.38 per share a year ago.
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Stifel initiated coverage on Cytokinetics Incorporated CYTK, noting the company's catalyst rich one to two years.
Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution
Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy (HCM). Strategic licensing deals with Sanofi and Bayer secure resources and focus US commercialization. Clinical trials aim to expand aficamten's utility, including first-line and pediatric indications.
Why Cytokinetics Stock Was a Nearly 5% Winner Today
California-based biotech Cytokinetcs (CYTK 4.56%) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in a key market abroad was the catalyst for the increase, which well exceeded the slightly over 1% gain of the S&P 500 index.
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
